North American GIS business drives profit beat; target price raised to ¥2,300

Overview

Olympus reported FY3/27 first-quarter results, with sales of ¥240.4bn, in line with Goldman Sachs' forecast; adjusted operating profit reached ¥30.7bn, about 24% above Goldman Sachs' forecast. The profit beat was mainly due to continued strength in the high-margin North American Gastrointestinal Endoscopy Solutions business and slower-than-expected recognition of R&D expenses. The company maintained its full-year guidance unchanged, but believes the strong start has increased confidence in achieving full-year targets.

Core views

Goldman Sachs believes Olympus's core competitiveness still comes from its globally leading gastrointestinal endoscopy business, with a global market share of about 70%, while the rollout of EVIS X1 and EDOF products in North America provides near-term earnings support. Based on upward revisions to GIS sales forecasts and lower R&D expense assumptions, Goldman Sachs raised its FY3/27 to FY3/31 operating profit forecasts by 2% to 4%. However, investors still need to validate margin improvement under the new management strategy, business mix optimization, and global competitiveness, while the FDA warning letter and import alert have not yet been lifted. Given that the valuation discount relative to peers is at its five-year historical average, the current valuation is not particularly attractive, so the Neutral rating is maintained.

Analysis framework

The report compares actual quarterly results with Goldman Sachs forecasts and company guidance, breaks down earnings differences by GIS and SIS businesses, and adjusts sales and R&D expense assumptions accordingly; the target price uses an FY3/28E EV/EBITDA relative valuation approach, while also incorporating the GS Factor Profile, peer comparisons, and M&A probability framework to assess the stock's growth, returns, valuation, and potential catalysts.

Methodology notes

• Relative valuationFY3/28E EV/EBITDA

  Determine the target price using the global medtech industry average valuation as the benchmark

  The target price is based on the global medtech industry's FY3/28E average EV/EBITDA of 12.0x, with a 10% discount applied to Olympus; the industry benchmark multiple was raised from 11.0x to 12.0x, lifting the target price to ¥2,300.

• Multi-factor analysisGS Factor Profile

  Compare growth, financial returns, valuation multiples, and overall performance

  The growth dimension references forward revenue, EBITDA, and EPS growth; financial returns reference ROE, ROCE, and CROCI; the valuation dimension references P/E, P/B, dividend valuation, and EV-based multiples; the integrated metric combines standardized percentiles of the first three items.

• M&A analysisM&A Rank

  Assess the probability of the company becoming an acquisition target

  Olympus's M&A Rank is 3, corresponding to a relatively low probability of becoming an acquisition target, about 0% to 15%, so M&A factors are not incorporated into the target price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Olympus (7733.T) shares

  The Japanese medtech company stock directly covered by this report

  Strengths

  Global gastrointestinal endoscopy market share of about 70%; the North American GIS business has relatively high margins and the rollout of EVIS X1 and EDOF products is proceeding smoothly; the company continues to focus on medical devices and advance margin improvement.

  Weaknesses

  The SIS business still records losses; the contribution of lower-than-expected R&D expenses to quarterly profit may be timing-related; the valuation discount relative to peers is only at its historical average.

  Comparison

  The target price is based on the global medtech industry's FY3/28E average EV/EBITDA of 12.0x with a 10% discount; Goldman Sachs believes the current relative valuation versus peers is not particularly cheap.

  Risks

  FDA warning letter and import alert, changes in global regulation, the Chinese medtech market environment, exchange rate fluctuations, inflation, manufacturing and sales, product R&D, competition, growth investments, and geopolitical risks.

Key data

• 1Q sales¥240.4bnIn line with Goldman Sachs' forecast of ¥240.4bn.
• 1Q adjusted operating profit¥30.7bnAbout 24% above Goldman Sachs' forecast of ¥24.8bn.
• 1Q R&D expenses¥20.9bnAbout 10% below Goldman Sachs' forecast of ¥23.2bn, one reason for the profit beat.
• GIS segment operating profit¥38.6bnAbout 23% above Goldman Sachs' forecast of ¥31.5bn.
• FY3/27 to FY3/31 operating profit forecast revisionRaised by 2% to 4%Mainly reflecting higher GIS sales forecasts and lower R&D expense assumptions.
• 12-month target price¥2,300Previously ¥2,050; implies 20.7% upside versus the current price of ¥1,906.
• FY3/28E operating profit forecast¥155.4bnPrevious forecast was ¥149.2bn.
• Global gastrointestinal endoscopy market shareAbout 70%Reflects Olympus's global competitive advantage in the core endoscopy market.
• Market capitalization¥2.1tr / $13.6bnKey market data listed in the report.
• Enterprise value¥2.2tr / $13.9bnKey market data listed in the report.

Impact & implications

These results show that Olympus's core GIS business, especially in North America, has strong product rollout and profitability capabilities, which should help improve the probability of achieving full-year guidance in the near term. Slower R&D expense recognition also brings upside to profit, but its sustainability needs to be verified in subsequent quarters. The target price increase reflects improved earnings forecasts and a rebound in medtech industry valuations, but the Neutral rating indicates that the current share price does not yet offer sufficient risk-adjusted appeal; further re-rating will depend more on continued GIS sales growth, improvement in SIS losses, delivery of management's margin initiatives, and removal of FDA regulatory restrictions.

Risks

• The removal of the FDA warning letter and import alert progresses more slowly than expected.
• North American GIS demand or the rollout of EVIS X1 and EDOF products falls short of expectations.
• R&D expense recognition accelerates later, making the current profit beat difficult to sustain.
• Execution of margin improvement measures and business mix optimization falls short of expectations.
• The Chinese medtech market environment deteriorates or global regulatory requirements change.
• The yen appreciates or depreciates more than expected, or inflation and manufacturing costs fluctuate.
• Risks related to product development, production and sales, competitive landscape, and growth investments.
• The spread of infectious diseases and geopolitical events affect global operations.
• Goldman Sachs disclosed that it has shareholding and client relationships with Olympus, which may constitute potential conflicts of interest.

What to watch

• Sales and margin trends in the core GIS business in subsequent quarters.
• Hospital adoption speed of EVIS X1 and EDOF endoscopes in North America.
• Pace of R&D expense recognition and sustainability of the profit beat.
• Progress toward achieving FY3/27 full-year guidance and whether management raises guidance.
• Narrowing of SIS business losses and overall margin improvement measures.
• Execution results of business mix optimization and the new management strategy.
• Progress in lifting the FDA warning letter and import alert.
• Changes in the valuation discount relative to global medtech peers.